Hikal Limited

Hikal Limited (HIKAL) is a micro-cap Healthcare company valued at ₹2,657 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Hikal Limited last traded at ₹216, modestly down 0.22% on the day.

Recent developments

On 2026-06-30, the company reported a net loss of ₹49 crore for the fiscal year ending March 2026, marking a significant swing from the prior year's profit. The company also announced a dividend of ₹0.40 per share on 2026-09-04 and a dividend of ₹0.20 per share on 2026-02-17.

Financial performance

The company's business has deteriorated, with annual revenue falling 7.9% to ₹1,713 crore and net profit swinging to a loss of ₹49 crore from a profit of ₹91 crore. The latest quarter saw revenue rise 5.9% year-on-year to ₹403 crore, but net profit narrowed from a loss of ₹22 crore to ₹7 crore.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 2.42 times book value.

Things to watch

The company reported a net loss of ₹49 crore for the latest fiscal year, with net profit margin at -2.8%, down 7.7 percentage points from the prior year. The return on equity and return on capital employed are both negative, indicating poor profitability. The stock is 16.4% below its 52-week high.

Where it stands

The company is currently reporting a net loss of ₹49 crore, with revenue declining annually and net profit margin worsening. The latest quarter showed some improvement, with a narrower loss, but the overall financial position remains weak. The stock is 16.4% below its 52-week high.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.